key: cord-1048698-1fqdqcrx
authors: Fernández‐Ruiz, Mario; Olea, Beatriz; Almendro‐Vázquez, Patricia; Giménez, Estela; Marcacuzco, Alberto; San Juan, Rafael; Justo, Iago; Calvo‐Pulido, Jorge; García‐Sesma, Álvaro; Manrique, Alejandro; Caso, Oscar; Cambra, Félix; Talayero, Paloma; López‐Medrano, Francisco; Remigia, María José; Ruiz‐Merlo, Tamara; Parra, Patricia; Paz‐Artal, Estela; Jiménez, Carlos; Loinaz, Carmelo; Navarro, David; Laguna‐Goya, Rocío; Aguado, José María
title: T cell–mediated response to SARS‐CoV‐2 in liver transplant recipients with prior COVID‐19
date: 2021-06-05
journal: Am J Transplant
DOI: 10.1111/ajt.16708
sha: 40a766983787579bd3187ac2fc457b8182203d5c
doc_id: 1048698
cord_uid: 1fqdqcrx

Whether immunosuppression impairs severe acute respiratory syndrome coronavirus 2‐specific T‐cell‐mediated immunity (SARS‐CoV‐2‐CMI) after liver transplantation (LT) remains unknown. We included 31 LT recipients in whom SARS‐CoV‐2‐CMI was assessed by intracellular cytokine staining (ICS) and interferon (IFN)‐γ FluoroSpot assay after a median of 103 days from COVID‐19 diagnosis. Serum SARS‐CoV‐2 IgG antibodies were measured by ELISA. A control group of non‐transplant immunocompetent patients were matched (1:1 ratio) by age and time from diagnosis. Post‐transplant SARS‐CoV‐2‐CMI was detected by ICS in 90.3% (28/31) of recipients, with higher proportions for IFN‐γ‐producing CD4(+) than CD8(+) responses (93.5% versus 83.9%). Positive spike‐specific and nucleoprotein‐specific responses were found by FluoroSpot in 86.7% (26/30) of recipients each, whereas membrane protein‐specific response was present in 83.3% (25/30). An inverse correlation was observed between the number of spike‐specific IFN‐γ‐producing SFUs and time from diagnosis (Spearman's rho: ‐0.418; P‐value = 0.024). Two recipients (6.5%) failed to mount either T‐cell‐mediated or IgG responses. There were no significant differences between LT recipients and non‐transplant patients in the magnitude of responses by FluoroSpot to any of the antigens. Most LT recipients mount detectable —but declining over time— SARS‐CoV‐2‐CMI after a median of 3 months from COVID‐19, with no meaningful differences with immunocompetent patients.

The coronavirus disease 2019 (COVID- 19) pandemic has disrupted liver transplantation (LT) programs worldwide. Although the clinical course and outcomes of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection seem to be better for LT recipients compared to other transplant groups [1] , mortality rates among hospitalized patients during the first wave reached 20% [2, 3] .

The understanding of the magnitude and durability of natural immunity following SARS-CoV-2 infection among immunocompromised patients is of paramount relevance to determine the individual susceptibility to reinfection. Previous studies have assessed SARS-CoV-2-specific T-cell-mediated immunity (SARS-CoV-2-CMI) in kidney transplant (KT) recipients recovered from COVID-19, revealing that interferon (IFN)γ-producing CD4 + and CD8 + T-cells reactive to the spike (S) glycoprotein and other structural proteins may be detected for at least 6 months [4] [5] [6] [7] . Specific data for LT recipients, however, are lacking. Variations in the magnitude of SARS-CoV-2-specific responses according to the type of immunosuppression, severity of COVID-19 and timing from transplantation are still largely unknown.

The present study was aimed at analyzing the frequencies of SARS-CoV-2-specific IFN-γ-producing T-cell responses and their clinical correlates in a single-center cohort of LT recipients at various times from the diagnosis of COVID-19. To this end, we used two different methods: the intracellular cytokine staining (ICS) and a fluorescent ELISpot for cytokine secretion (IFN-γ FluoroSpot assay).

This article is protected by copyright. All rights reserved

All adult LT recipients regularly seen at the University Hospital " 12 The management of LT recipients with post-transplant COVID-19 -including the use of antiviral agents, immunomodulatory therapies and supportive care-was in accordance with the national and local guidelines in place at each time, which have evolved throughout the study period according to the available evidence [8, 9] . Once recovered, patients were followed-up until January 2021 by phone calls or at the outpatient clinic according to routine practice, in order to assess the development of symptoms compatible with SARS-CoV-2 reinfection.

Whole blood specimens were collected in sodium heparin tubes and shipped at room temperature to the Hospital Clínico Universitario (Valencia, Spain), where they were processed within 24 hours. Enumeration of SARS-CoV-2-specific IFN-γ-producing CD69 + CD4 + and CD8 + T-cells was performed by flow cytometry for ICS (BD Fastimmune TM kit, BD Biosciences, San Jose, CA) following a protocol originally designed for the assessment of cytomegalovirus (CMV)-specific cell-mediated immunity [10, 11] . In brief, heparinized whole blood (0.5 mL) was simultaneously stimulated for 6 hours with two sets of 15-mer overlapping peptides (11-mer overlap) encompassing the SARS-CoV-2 S glycoprotein N-terminal 1-to 643-amino acid sequence (158 individual peptides) (PepMix™ SARS-CoV-2 Spike Glycoprotein, JPT peptide Technologies GmbH, Berlin, Germany) and the entire sequence of the membrane (M) protein (53 peptides) (Epitope Mapping Peptide Set [EMPS] SARS-CoV-2 VME1, JPT) at a concentration of 1 μg/mL per peptide and in the presence of costimulatory monoclonal antibodies (mAbs) targeting CD28 and CD49d (1 μg/mL).

Brefeldin A (10 μg/mL) was added for the last 4 hours of incubation. Next, blood was lysed (BD FACS lysing solution) and frozen at -80°C. On the day of testing, stimulated blood was thawed at 37°C, washed, permeabilized (BD permeabilizing solution) and stained with fluorochrome-labeled mAbs (anti-CD3-APC-Cy7, anti-CD69-PE, anti-CD4 or CD8-PerCP-Cy5.5, and anti-IFN-γ-FITC) for one hour at room temperature. Samples mock-stimulated with phosphate-buffered saline (PBS)/dimethyl sulfoxide solution (without peptides) and costimulatory antibodies or stimulated with phytohemagglutinin (1 mg/mL) as nonspecific mitogen (Sigma-Aldrich, St. Louis, MO) were run in parallel in all experiments. Appropriate isotype controls were also used. Next, cells were washed, resuspended in 200 μL of 1% paraformaldehyde in PBS,

This article is protected by copyright. All rights reserved and analyzed within 2 hours on a FACScanto flow cytometer using BD FACSDiva TM software (BD Biosciences, San Jose, CA). CD3 + /CD4 + and CD3 + /CD8 + events were gated and analyzed for the T-cell activation marker CD69 + and IFN-γ production. SARS-CoV-2-specific IFN-γ-producing CD69 + CD4 + and CD8 + T-cells were enumerated by multiplying the corresponding percentages of T-cells that produced IFN-γ upon peptide stimulation (after background subtraction) by absolute CD4 + and CD8 + T-cell counts, and responses ≥0.1% were considered specific.

Whole blood specimens were processed at the Department of Immunology of the Hospital Universitario "12 de Octubre" within 24 hours from sampling. Peripheral blood mononuclear cells (PBMCs) were freshly isolated by density-gradient centrifugation using Ficoll-Paque and seeded at 300,000 cells/well in IFN-γ FluoroSpot TM plates (MabTech, Nacka Strand, Sweden) with cell culture medium containing RPMI, 1% Lglutamine, 1% penicillin/streptomycin, 10% fetal bovine serum and anti-CD28 mAb (1 µg/mL). Test wells were performed in duplicate and supplemented with 15-mer overlapping peptides covering the S1 domain Results were excluded if negative control wells had >80 SFUs/10 6 PBMCs or positive control wells had <400 SFUs/10 6 PBMCs. Reponses were considered positive if the results were at least three times higher than the mean of the negative control wells and above of the following antigen-specific cut-off values (which had been established by using a control group of 30 healthcare workers with no microbiological, serological or clinical evidence of SARS-CoV-2 infection): >25 SFUs/10 6 PBMCs for the S glycoprotein (S1 domain), >14 SFUs/10 6 PBMCs for the N protein, and >21 SFUs/10 6 PBMCs for the M protein.

Serum SARS-CoV-2 IgG antibodies targeting the S1 protein were detected with the Euroimmun Anti-SARS-CoV-2 enzyme-linked immunosorbent assay (ELISA) (Euroimmun AG, Lübeck, Germany) according to manufacturer's instructions. Optical density (OD) values were measured at 450 nm using the PR 3100 microplate reader (Bio-Rad Life Science, Marnes-La-Coquette, France). Results were evaluated semiquantitatively by calculating the ratio of the OD value of the sample over the OD value of the calibrator (relative OD), with the following cut-off values: ratio <0.8: negative; ratio ≥ 0.8 to <1.1: borderline; and ratio ≥1.1: positive.

This article is protected by copyright. All rights reserved In order to analyze the impact of post-transplant immunosuppression on the development and magnitude of SARS-CoV-2-CMI measured by the IFN-γ FluoroSpot assay, we selected a group of immunocompetent patients diagnosed with COVID-19 that were hospitalized at our institution in March 2020. Non-transplant controls were matched in a 1:1 ratio with LT recipients according to age and time interval from the diagnosis of COVID-19 to the assessment of SARS-CoV-2-CMI. None of the controls had other causes of immunosuppression (i.e. active malignancy, HIV infection or chronic corticosteroid therapy).

Quantitative data were shown as the mean ± standard deviation (SD) or the median with interquartile range (IQR), and qualitative variables were expressed as absolute and relative frequencies. Categorical variables were compared using the χ 2 test. The Mann-Whitney U test was applied for continuous variables.

Correlations between continuous variables were evaluated using the Pearson's correlation coefficient or the Spearman's rho. The agreement between both methods used for assessing SARS-CoV-2-CMI (ICS and 

This article is protected by copyright. All rights reserved

Overall, 35 LT recipients regularly followed-up at our institution with a RT-PCR-confirmed diagnosis of SARS-CoV-2 infection between March 15 and November 13 were approached. Four of them refused to participate, and 31 patients (88.6%) were finally included ( Table 1) 

Any SARS-CoV-2-CMI (≥0.1%) was detectable by ICS in 90.3% (28/31) of patients. In detail, SARS-CoV-2specific IFN-γ-producing CD4 + and CD8 + T-cell responses were observed in 90.3% (28/31) and 83.9% (26/31), respectively. Absolute counts were 2.8 ± 2.0 CD4 + T-cells/μL and 1.9 ± 2.1 CD8 + T-cells/μL. One recipient -a 57-year-old female patient that had undergone LT 16 years earlier and was on tacrolimuslacked any detectable T-cell response after 290 days from the diagnosis of COVID-19.

When SARS-CoV-2-specific T-cell counts were analyzed according to the interval from the diagnosis of COVID-19, there was a non-significant decrease over time for both CD4 + (3.3 ± 2.3 versus 2.1 ± 1.6 cells/μL from 30-90 days to >180 days; P-value = 0.153) and CD8 + T-cell subsets (2.7 ± 2.7 versus 1.6 ± 1.8 cells/μL, respectively; P-value = 0.223) (Figure 1) .

Any SARS-CoV-2-CMI was detectable by the IFN-γ FluoroSpot assay in 90.0% (27/20) of patients (one sample was not evaluable). In detail, positive S glycoprotein-specific (>25 SFUs/10 6 PBMCs) and N proteinspecific (>14 SFUs/10 6 PBMCs) responses were present in 86.7% (26/30) each, whereas the rate of M protein-specific response (>21 SFUs/10 6 PBMCs) was 83.3% (25/30).

We also analyzed T-cell responses in a continuous manner according to the time elapsed from COVID-19.

The magnitude of S glycoprotein-specific (514 ± 387 versus 174 ± 267 SFUs/10 6 PBMCs; P-value = 0.004) and M protein-specific responses (263 ± 226 versus 104 ± 87 SFUs/10 6 PBMCs; P-value = 0.038) decreased from the first (30-90 days) to the last time interval analyzed (>180 days), respectively (Figure 2 ).

An inverse correlation was accordingly found between the number of S glycoprotein-specific IFNγ-producing SFUs per 10 6 PBMCs and the interval from COVID-19 diagnosis (Spearman's rho: -0.418; Pvalue = 0.024), reflecting a decrease in the magnitude of response over time.

We restricted this analysis to T-cell responses against the S glycoprotein and the N protein by the FluoroSpot assay, since these were the viral antigens used for stimulation in the ICS method. We found a

This article is protected by copyright. All rights reserved (Table S1 ) or immunosuppressive drug levels ( Table S2) .

Finally, we compared SARS-CoV-2-specific T-cell responses by the IFN-γ FluoroSpot assay in LT

This article is protected by copyright. All rights reserved recipients and a non-transplant control group of 30 immunocompetent patients matched by age and time from COVID-19 (Table S3) . As expected, the interval from the initial diagnosis of SARS-CoV-2 to the SARS-CoV-2-CMI measurement was similar both groups (158.0 ± 94.9 versus 162.5 ± 29.9 days, respectively; P-value = 0.809).

We observed no significant differences between LT recipients and non-transplant patients in the proportion of detectable T-cell responses to the S glycoprotein (86.7% [26/30] 6 PBMCs for any of these antigens was also comparable (Figure 4, Table 2 ).

This article is protected by copyright. All rights reserved

In the present cross-sectional study the functionality and magnitude of SARS-CoV-2-CMI have been analyzed by means of two methods in a cohort of 31 LT recipients at different time intervals from the diagnosis of COVID-19. The clinical severity of SARS-CoV-2 infection was also variable, with about two thirds of the recipients being managed as outpatients. The main finding is that the majority of LT recipients recovered from COVID-19 had detectable SARS-CoV-2-CMI (90.3% by ICS and 90.0% by ELISpot-based IFN-γ FluoroSpot assay) after a median of 103 days, and exceeding 6 months in some patients. In addition, anti-SARS-CoV-2 S1 protein IgG was detected in 90.3% of patients. No differences were evident in the proportion of positive SARS-CoV-2-specific T-cell responses or in the number of IFN-γ-producing SFUs targeting each of the structural proteins investigated between LT recipients and non-transplant patients matched by age and time from diagnosis. These findings collectively indicate that immunosuppression has no meaningful impact on the long-term ability to mount specific T-cell-mediated immunity elicited by natural

Only a few studies have analyzed the kinetics of SARS-CoV-2-CMI in solid organ transplant (SOT) recipients following COVID-19 [4] [5] [6] [7] 12, 13] , and none of them were focused on the LT population. By means of an ELISpot assay, Candon et al. characterized SARS-CoV-2-specific T-cells in a small group of KT recipients at a shorter interval from symptom onset than in our cohort (median of 38.5 days). All recipients with confirmed SARS-CoV-2 infection displayed CD4 + and CD8 + T-cells reactive to at least 6 of 9 viral peptides, with frequencies similar to the non-transplant patients on hemodialysis [4] . In a larger cohort, we previously reported that SARS-CoV-2-CMI was present by ICS in 57.1% and 57.9% of KT recipients at months 4 and 6 after the diagnosis, respectively [5] . In other study, SARS-CoV-2-specific CD4 + polyfunctional T-cell responses were detected in 9 out of 10 patients -most of them KT recipients-during the acute phase of COVID-19 [6] . Hartzell et al. reported that stable KT recipients on tacrolimus-based immunosuppression hospitalized due to COVID-19 exhibited changes in peripheral blood immune cell phenotypes similar to those observed in the general population [12] .

All-cause mortality rates among SOT recipients hospitalized due to COVID-19 during the first pandemic wave have been reported to exceed that of the general population [1, 3] . Although outcomes for LT recipients seem to be relatively better as compared to other transplant groups, the pooled estimate for inhospital mortality in a recent meta-analysis reached 20% [14] . However, it has been recently proposed that the more severe course observed for post-transplant COVID-19 could be attributed to the higher burden of comorbidities and more common presence of risk factors for poor outcome (such as older age or acute kidney injury) rather than to the transplant status itself [15] [16] [17] [18] . The absence of significant differences in between LT recipients and matched non-transplant patients in the magnitude of SARS-CoV-2-CMI would support this notion. Thieme et al. also reported that SARS-CoV-2-specific M-and S-reactive polyfunctional CD8 + T-cell counts and neutralizing antibody-titers did not differ between SOT recipients and nontransplant controls [6] . In a mixed cohort of SOT recipients, Favà et al. demonstrated the development of robust serological and functional responses comparable to non-transplant patients during early convalescence [7] . Studies performed in other types of immunocompromised hosts have reached similar

This article is protected by copyright. All rights reserved conclusions [19] . Overall, these findings emphasize the need of taking into account not only the seroconversion rate but also the development of T-cell-mediated immunity in studies assessing the immunogenicity of SARS-CoV-2 vaccines in the SOT population [20] .

While there is a long-standing technical and clinical experience with the quantification of CMV-specific Tcell responses in the SOT setting [21] , the optimal methodological approach for the assessment of posttransplant SARS-CoV-2-CMI remains to be established. Thus, we have applied two different techniques that offer complementary results. The ICS method is able to phenotype T-cell responses (CD4 + versus CD8 + ), whereas the IFN-γ FluoroSpot assay informs on the viral antigen-specificity of such responses. In accordance with our previous study performed in KT recipients [5] , the results of the FluoroSpot assay correlate with CD4 + but not CD8 + T-cell responses enumerated by ICS. In addition, the categorical agreement -albeit moderate-was higher for the immunodominant S glycoprotein. It should be noted, however, that both methods are not entirely comparable in terms of sample analyzed (whole blood versus PBMCs) and duration of antigen stimulation (6 versus 16-18 hours). On the other hand, there were differences in the S peptides used for in vitro stimulation. Specific T-cells enumerated by ICS were reactive to both subdomains (S1 and S2) of the viral glycoprotein, whereas the FluoroSpot assay only detected responses against the S1 subdomain. It could be hypothesized that the ICS method would be able to detect a larger T-cell repertoire elicited by both natural infection and vaccination.

In line with studies performed in the general population [22] , we observed a significant decline over time in the S glycoprotein-specific T-cell response assessed by the IFN-γ FluoroSpot assay (which was not mirrored by the results obtained for other antigens or with the ICS method). In addition, the high proportion of detectable SARS-CoV-2-CMI by ICS after a median of 3.4 months contrasts with that observed by our group with the same method among KT recipients, which only reached 57.1% and 19.0% for SARS-CoV-2specific CD4 + and CD8 + T-cell responses, respectively, at month 4 [5] . Differences in the type and amount of immunosuppression may account for such discrepancy. Indeed, most of the KT recipients in our previous study were receiving a triple regimen based on a calcineurin inhibitor, an antiproliferative agent and prednisone [5] , whereas 54.8% of LT recipients were on monotherapy (mainly mofetil mycophenolate).

Consistent with this, patients receiving prednisone or tacrolimus or prednisone at the time of immune assessment exhibited lower SARS-CoV-2-specific T-cell responses by the FluoroSpot assay. The deleterious impact of tacrolimus-containing regimens on the capacity of mounting SARS-CoV-2-CMI was also observed in the setting of KT [5] . Interestingly, we observed no apparent effect of the clinical severity of COVID-19 (i.e. requirement of hospitalization or oxygen therapy) on the magnitude of T-cell responses.

Some [23] [24] [25] but not all 22, 26] have found a positive correlation between clinical severity at early phases of infection and SARS-CoV-2-specific T-cell counts in non-transplant patients, although studies differ in the timing of evaluation. Increasing evidence shows that subjects with asymptomatic SARS-CoV-2 infection are able to mount specific T-cell responses comparable to those observed in patients recovering from COVID-19 [22] . It is to be assumed that this concept also extends to LT recipients, since most of the patients in our cohort had only mild clinical manifestations and were managed as outpatients.

This article is protected by copyright. All rights reserved Although this is the largest study to date investigating SARS-CoV-2-CMI after SOT (and the only one focused on LT recipients and applying different methods), some limitations should be acknowledged. The number of patients included was relatively low, particularly for the more severe courses of disease. Therefore, no multivariate analysis was performed and the clinical associations observed (i.e. type of immunosuppression) should be taken with caution. Despite matching by age and time from diagnosis, LT recipients and non-transplant controls differed in some clinical characteristics, since all the patients in the latter group required hospital admission (as compared to only 38.7% in the LT group). Thus, the lack of apparent differences in the magnitude of SARS-CoV-2-CMI could be at least partially explained by the characteristics of the control cohort, since immunocompetent patients unable to mount robust T-cellmediated responses early after infection are more likely to progress to severe symptoms (P. Almendro-Vázquez, Instituto de Investigación Sanitaria Hospital "12 de Octubre", personal communication, 2021).

Nevertheless, a sensitivity analysis restricted to hospitalized LT recipients and their corresponding controls (12 pairs) did not reveal differences between both groups in the size of T-cell responses (data not shown). 

This article is protected by copyright. All rights reserved

The authors have no conflicts of interest to disclose as described by the American Journal of Transplantation.

This work was supported by the Instituto de Salud Carlos III (ISCIII), Spanish Ministry of Science and Innovation (COVID-19 Research Call COV20/00181) -co-financed by European Development Regional 

This article is protected by copyright. All rights reserved and non-transplant patients matched by age and time interval from the diagnosis of COVID-19.

Comparisons were performed with the Mann-Whitney U test. 

COVID-19 in transplant recipients: The Spanish experience

Epidemiological pattern, incidence, and outcomes of COVID-19 in liver transplant patients

COVID-19 in solid organ transplant: A multi-center cohort study

T cell and antibody responses to SARS-CoV-2: experience from a French transplantation and hemodialysis center during the COVID-19 pandemic

SARS-CoV-2-specific cell-mediated immunity in kidney transplant recipients recovered from COVID-19

The magnitude and functionality of SARS-CoV-2 reactive cellular and humoral immunity in transplant population is similar to the general population despite immunosuppression

SARS-CoV-2-specific serological and functional T-cell Immune responses during acute and early COVID-19 convalescence in Solid Organ Transplant patients

Varied clinical presentation and outcome of SARS-CoV-2 infection in liver transplant recipients

Enumeration of cytomegalovirusspecific interferon-γ CD8+ and CD4+ T cells early after allogeneic stem cell transplantation may identify patients at risk of active cytomegalovirus infection

SARS-CoV-2-reactive interferon-γ-producing CD8 + T cells in patients hospitalized with coronavirus disease 2019

Evidence of potent humoral immune activity in COVID-19-infected kidney transplant recipients

Immune responses to SARS-CoV-2 in solid organ transplant recipients

COVID-19 in hospitalized liver transplant recipients: An early systematic review and meta-analysis

Outcomes of coronavirus infectious disease-19 (COVID-19) in solid organ transplant recipients

Clinical characteristics and outcomes of COVID-19 in solid organ transplant recipients: A cohort study

Is COVID-19 infection more severe in kidney transplant recipients?

A propensity score-matched analysis of mortality in solid organ transplant patients with COVID-19 compared to non-solid organ transplant patients

Evidence of robust memory Tcell responses in patients with chronic myeloproliferative neoplasms following infection with severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2)

Immunogenicity of a single dose of SARS-CoV-2 messenger RNA vaccine in solid organ transplant recipients

ABC" of virus-specific T cell immunity in solid organ transplantation

Highly functional virus-specific cellular immune response in asymptomatic SARS-CoV-2 infection

Broad and strong memory CD4+ and CD8+ T cells induced by SARS-CoV-2 in UK convalescent individuals following COVID-19

Robust T cell immunity in convalescent individuals with asymptomatic or mild COVID-19

Antigenspecific adaptive immunity to SARS-CoV-2 in acute COVID-19 and associations with age and disease severity

Early induction of functional SARS-CoV-2-specific T cells associates with rapid viral clearance and mild disease in COVID-19 patients

Relative OD values of SARS-CoV-2 IgG ELISA

This article is protected by copyright. All rights reserved Additional supporting information may be found online in the Supporting Information section at the end of the article.